Savient Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Savient Pharmaceuticals, Inc.
The European Medicines Agency has added 13 new drugs to its list of products that are under review for potential pan-EU marketing approval.
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.
Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.
Keeping Track: US FDA Approval Binge Includes Brexafemme, Wegovy, Ryplazim, Truseltiq, Lybalvi, Tembexa
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Other Names / Subsidiaries
- Bio-Technology General Corporation